News | February 28, 2010

Patients Prefer Iohexol Contrast Over Diatrozoate

February 28, 2010 - Patients expressed a statistically significant preference for the taste of iohexol over diatrozoate, a feature that is especially beneficial for very ill patients whom have trouble tolerating the taste of contrast agents, concluded a recent study.

Researchers from Mallinckrodt Institute of Radiology at the Washington University School of Medicine, St. Louis, Missouri and the Milton S. Hershey Penn State Medical Center conducted a study comparing the tolerability of iodine-based oral contrast agents, Omnipaque (iohexol) and Gastroview (meglumine sodium diatrizoate). The purpose of the study was to compare the efficacy and patient acceptance of iohexol verus meglumine sodium diatrozoate for abdominal and pelvic CT scans.

Researchers presented on February 21 at the Abdominal Radiology Course Meeting held by the Society of Gastrointestinal Radiology and The Society of Uroradiology in Orlando.

The study also concluded that:

- There was no statistically significant difference between the two agents in the incidence of adverse reactions.

- The extent and density of GI tract opacification also were similar between the two groups.

- The cost of the two agents is comparable given the current low cost of low osmolar contrast agents.

For more information:

Related Content

ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents
News | Contrast Media | August 15, 2017
The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in the use of contrast...
Contrast Media from Bayer, trends in contrast media and developments in contrast media
Feature | Contrast Media | July 28, 2017 | By Dave Fornell
Here are several updates in medical imaging ...
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media | July 18, 2017
July 18, 2017 — Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabri
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media | July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
FDA says gadolinium retention in the brain is not a safety issue
Feature | Magnetic Resonance Imaging (MRI) | May 25, 2017
A U.S. Food and Drug Administration (FDA) review of the safety ramifications of gadolinium-based contrast agents for...
Targeted MRI Could Pinpoint Aggressive Prostate Cancers Before They Spread

The ZD2-Gd probe, represented by the orange ball and green arrow, binds to the EDB-FN in the prostate cancer cells with high metastatic potential. This results in a strong MRI signal (upper right). Prostate cancer cells with low metastatic potential have no EDB-FN and so there is no MRI signal (lower right). Credit: Han, et al., Bioconjug Chem-Apr-2017

News | Prostate Cancer | May 24, 2017
A research team funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) has engineered a...
Scientists Develop Novel Chemical Dye to Improve MRI Liver Cancer Imaging
News | Magnetic Resonance Imaging (MRI) | May 03, 2017
May 3, 2017 — Scientists from the National University of Singapore (NUS) have developed a novel nanodiamond-based ...
Sponsored Content | Case Study | Contrast Media Injectors | April 13, 2017
The volume of computed tomography (CT) imaging exams continues to grow in the United States,[2] adding pressure to...
PRAC, European Medicines Agency, gadolinium-based contrast agents, safety recommendations, brain MRI
News | Contrast Media | March 13, 2017
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new...
Overlay Init